Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
A Phase 2b Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
Sponsor: HUYABIO International, LLC.
A PHASE2 clinical study on Adult T-Cell Lymphoma (ATL), this trial is completed. The trial is conducted by HUYABIO International, LLC. and has accumulated 13 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- HUYABIO International, LLC.
- Iqvia Pty Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Fukuoka, Japan , Isehara, Japan , Kagoshima, Japan , Miyagi, Japan , Miyazaki, Japan , Nagasaki, Japan , Nagoya, Japan , Okinawa, Japan , Saitama, Japan , Sapporo, Japan and 5 more locations